Isaacs, Claudine <br/><br/>
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.  [electronic resource] 

 -  Breast cancer research and treatment  Jan 2011 
 - 137-43 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-010-1226-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anastrozole<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Aromatase Inhibitors--administration & dosage<br/>Benzenesulfonates--administration & dosage<br/>Breast Neoplasms--chemistry<br/>Disease-Free Survival<br/>Drug Resistance, Neoplasm<br/>Endothelial Cells--drug effects<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Niacinamide--analogs & derivatives<br/>Nitriles--administration & dosage<br/>Phenylurea Compounds<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyridines--administration & dosage<br/>Receptors, Estrogen--analysis<br/>Receptors, Progesterone--analysis<br/>Sorafenib<br/>Stem Cells--drug effects<br/>Time Factors<br/>Treatment Outcome<br/>Triazoles--administration & dosage<br/>United States